Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NIDA-CTN-0134

Division

CTN

HEAL Study

Investigator(s)

LaTrice Montgomery, Ph.D.

T. John Winhusen, Ph.D.

Title

Identifying Regional “Hotspots” and Potential Correlates of Precipitated Withdrawal During Buprenorphine Induction in Fentanyl Users Through Prescriber Survey Responses and Patient Urine Drug Test Results (Buprenorphine-Precipitated Withdrawal Hotspots and Correlates)

Short Description

This study will characterize the regional variability in the prevalence of prescriber-reported precipitated withdrawal during BUP induction for individuals using fentanyl and other non-prescribed and/or illicit drugs in approximately 279 counties in the United States.

Release Date

Jun 03, 2025

Description

This study is a one group, cross-sectional survey study. Active buprenorphine (BUP) prescribers will be recruited to participate in an online survey of clinical program features, characteristics of patients with opioid use disorder (OUD), patients’ experience with precipitated withdrawal during BUP induction, and patients’ fentanyl use at a single time point. Millennium Health (MH) will provide urine drug test (UDT) results from the counties of prescribers who participated in the survey. Both the survey and UDT results will be obtained from addiction treatment clinics. The UDT results and survey data will be merged at the county level to assess the association between precipitated withdrawal issues and fentanyl, fentanyl analogues, and other drugs of abuse.

Keywords